2. Search Result
Search Result
Results for "

rat hippocampal slice

" in MedChemExpress (MCE) Product Catalog:

23

阻害剤およびアゴニスト

4

ペプチド

1

天然物

製品番号 製品名 Target 研究分野 構造式
  • HY-P1388
    β-Amyloid (1-42), (rat/mouse)
    Maximum Cited Publications
    8 Publications Verification

    Amyloid β-peptide (1-42) (rat/mouse)

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-42), (rat/mouse) is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.
    β-Amyloid (1-42), (rat/mouse)
  • HY-10932
    Aniracetam
    1 Publications Verification

    Ro 13-5057

    		 nAChR iGluR Neurological Disease
    Aniracetam (Ro 13-5057) is an orally active neuroprotective agent, possessing nootropics effects. Aniracetam potentiates the ionotropic quisqualate (iQA) responses in the CA1 region of rat hippocampal slices. Aniracetam also potentiates the excitatory post synaptic potentials (EPSPs) in Schaffer collateral-commissural synapses. Aniracetam can prevents the CO2-induced impairment of acquisition in hypercapnia model rats. Aniracetam can be used to research cerebral dysfunctional disorders .
    Aniracetam
  • HY-B0696
    Tiagabine

    NO050328; NO328; TGB

    		 GABA Receptor Neurological Disease
    Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
    Tiagabine
  • HY-148226
    20-5,14-HEDGE

    		Apoptosis Reactive Oxygen Species (ROS) Cardiovascular Disease
    20-5,14-HEDGE is a 20-HETE analog. 20-5,14-HEDGE induces cell death in organotypic hippocampal slice cultures (OHSCs). 20-5,14-HEDGE enhances ROS production and reduces hypoxia-reoxygenation (HR)-induced apoptosis in ex vivo rat lung slices. 20-5,14-HEDGE protects against lung ischemic reperfusion injury in rats. 20-5,14-HEDGE can be used for the study of pulmonary vascular signaling and lung injury-related research .
    20-5,14-HEDGE
  • HY-125931
    Unifiram

    DM232

    		 iGluR Neurological Disease Inflammation/Immunology
    Unifiram (DM232) is a AMPA receptor activator and cognitive enhancer. Unifiram activates the AMPA-mediated neurotransmission system. Unifiram reverses NBQX-induced amnesia in the passive avoidance test in mice. Unifiram reverses the antagonistic effect of kynurenic acid on NMDA-mediated [ 3H]NA release in rat hippocampal slices. Unifiram enhances excitatory synaptic transmission in the rat hippocampus in vitro. Unifiram can be used in studies related to amnesia and cognitive dysfunction, including age-related memory decline, neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease, multiple sclerosis, schizophrenia, and attention deficit hyperactivity disorder .
    Unifiram
  • HY-P1388A
    β-Amyloid (1-42), (rat/mouse) TFA
    Maximum Cited Publications
    8 Publications Verification

    Amyloid β-peptide (1-42) (rat/mouse) TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-42), (rat/mouse) TFA is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.
    β-Amyloid (1-42), (rat/mouse) TFA
  • HY-P2259
    TAT-GluA2 3Y
    2 Publications Verification

    		 iGluR HIV Integrase Adenosine Receptor Cardiovascular Disease Neurological Disease
    TAT-GluA2 3Y is a blood-brain barrier-permeable AMPA receptor inhibitory peptide that crosses cell membranes via the HIV-1 TAT protein domain. TAT-GluA2 3Y blocks the endocytosis of AMPA receptors, including the internalization of GluA1/GluA2 subunits, by disrupting interactions with the AP2, Brag2 and Syt3-GluA2 complexes, while also inhibiting long-term depression. TAT-GluA2 3Y blocks hypoxia-mediated AMPAR internalization, alleviates A1R-induced persistent synaptic inhibition, and reduces cerebral ischemic volume, neurological deficits and spatial memory deficits. TAT-GluA2 3Y blocks the effect of NLRP3 deficiency on fear generalization, inhibits amphetamine-induced behavioral/neurochemical sensitization, weakens the unconditioned stimulus-conditioned stimulus association of morphine, and promotes the extinction of morphine CPP. TAT-GluA2 3Y can be used in studies related to fear generalization, ischemic stroke, hypoxia, drug addiction and opioid addiction .
    TAT-GluA2 3Y
  • HY-106865
    Mivazerol

    		Dopamine Receptor Adrenergic Receptor Cardiovascular Disease
    Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats, and exerts neuroprotective effects in forebrain ischemia rats. Mivazerol can be used for myocardial ischemia research .
    Mivazerol
  • HY-100743
    DL-AP4

    2-Amino-4-phosphonobutyric acid

    		 mGluR Neurological Disease Metabolic Disease
    DL-AP4 (2-Amino-4-phosphonobutyric acid) is a glutamate antagonist. DL-AP4 behaves as a competitive inhibitor of glutamate binding with an apparent Kd of 66 μM. DL-AP4 can be used for the research of central nervous system and visual system .
    DL-AP4
  • HY-10932R
    Aniracetam (Standard)

    Ro 13-5057 (Standard)

    		 Reference Standards nAChR iGluR Neurological Disease
    Aniracetam (Standard) is the analytical standard of Aniracetam. This product is intended for research and analytical applications. Aniracetam (Ro 13-5057) is an orally active neuroprotective agent, possessing nootropics effects. Aniracetam potentiates the ionotropic quisqualate (iQA) responses in the CA1 region of rat hippocampal slices. Aniracetam also potentiates the excitatory post synaptic potentials (EPSPs) in Schaffer collateral-commissural synapses. Aniracetam can prevents the CO2-induced impairment of acquisition in hypercapnia model rats. Aniracetam can be used to research cerebral dysfunctional disorders .
    Aniracetam (Standard)
  • HY-12701A
    U-99194 maleate

    U-99194A; PNU-99194A maleate; JPC-211 maleate

    		 Dopamine Receptor Neurological Disease
    U-99194 (PNU-99194) maleate is a selective, potent dopamine D3 receptor antagonist (Ki =160 nM). U-99194 maleate inhibits the activation of D3 receptor mediated by endogenously released dopamine or exogenous D3 agonists. U-99194 maleate abrogates the IPSC-suppressive effect of the D3 agonist PD 128907 in rat hippocampal slices. U-99194 maleate significantly suppresses Nicotine (HY-127019)-induced tremor in mice. U-99194 maleate can be used for the study of dopamine D3 receptor-mediated motor disorders, particularly kinetic tremors .
    U-99194 maleate
  • HY-171979
    Fluorolintane

    		iGluR Neurological Disease
    Fluorolintane exhibits high affinity for N-methyl-D-aspartate (NMDA) receptors with a Ki of 87.92 nM. Fluorolintane inhibits prepulse inhibition in rats. Fluorolintane also inhibits NMDA receptor-induced field excitatory postsynaptic potentials in rat hippocampal slices .
    Fluorolintane
  • HY-168771
    gamma-DGG TFA

    γDGG TFA; γ-D-Glutamylglycine TFA

    		 iGluR Neurological Disease
    gamma-DGG TFA is the antagonist for excitatory amino acid, that blocks NMDA-(HY-17551), Kainate-(HY-N2309) and Quisqualate-(HY-12597) induced depolarization, and antagonises the excitatory postsynaptic potential (e.p.s.p.) in rat hippocampal slices .
    gamma-DGG TFA
  • HY-107605
    UBP296

    		iGluR Neurological Disease
    UBP296 is a potent and selective antagonist of GLUK5-containing kainate receptor in the spinal cord. UBP296 reversibly blocks ATPA-induced depressions of synaptic transmission, and affects AMPA receptor-mediated synaptic transmission directly in rat hippocampal slices .
    UBP296
  • HY-P1424A
    Lei-Dab7 TFA

    		Potassium Channel Neurological Disease
    Lei-Dab7 TFA is a high affinity, selective KCa2.2 (SK2) channel blocker (Kd=3.8 nM). Lei-Dab7 TFA exhibits >200-fold selectivity for KCa2.2 over KCa2.1, KCa2.3, KCa3.1, Kv and Kir2.1. Lei-Dab7 TFA increases theta-burst responses and increases LTP in rat hippocampal slices in vitro.
    Lei-Dab7 TFA
  • HY-12701
    U-99194

    U-99194A free base; PNU-99194A; JPC-211

    		 Dopamine Receptor Neurological Disease
    U-99194 (PNU-99194) is a selective, potent dopamine D3 receptor antagonist. U-99194 inhibits the activation of D3 receptor mediated by endogenously released dopamine or exogenous D3 agonists. U-99194 abrogates the IPSC-suppressive effect of the D3 agonist PD 128907 in rat hippocampal slices. U-99194 significantly suppresses Nicotine (HY-127019)-induced tremor in mice. U-99194 can be used for the study of dopamine D3 receptor-mediated motor disorders, particularly kinetic tremors .
    U-99194
  • HY-100743R
    DL-AP4 (Standard)

    2-Amino-4-phosphonobutyric acid (Standard)

    		 mGluR Reference Standards Neurological Disease Metabolic Disease
    DL-AP4 (Standard) is the analytical standard of DL-AP4. This product is intended for research and analytical applications. DL-AP4 (2-Amino-4-phosphonobutyric acid) is a glutamate antagonist. DL-AP4 behaves as a competitive inhibitor of glutamate binding with an apparent Kd of 66 μM. DL-AP4 can be used for the research of central nervous system and visual system .
    DL-AP4 (Standard)
  • HY-116260
    RP-69758

    		Cholecystokinin Receptor Neurological Disease Inflammation/Immunology
    RP-69758 is a potent and selective non-peptide cholecystokinin-B (CCKB)/gastrin receptor antagonist. RP-69758 exhibits >200-fold selectivity for CCKB over CCKA receptors. RP-69758 antagonizes CCK-8-induced neuronal firing in rat hippocampal slices. RP-69758 inhibits Pentagastrin (HY-A0261)-induced gastric acid secretion in the rat. RP-69758 can be used for neurological disorders and gastrointestinal disease research .
    RP-69758
  • HY-182410
    EGIS-9637

    		iGluR Neurological Disease
    EGIS-9637 is a non-competitive AMPA antagonist and acylated dihydro-2,3-benzodiazepine class member .
    EGIS-9637
  • HY-204388
    TAK-137

    		iGluR Calcium Channel Neurological Disease
    TAK-137 is an AMPA receptor potentiator with weak agonistic effect. TAK-137 binds to the AMPA receptor ligand binding domain in a glutamate-dependent manner. TAK-137 potentiates AMPA-induced currents and Ca 2+ influx. TAK-137 can be used for the research of neurological disease .
    TAK-137
  • HY-W051199
    O-Phosphono-L-homoserine

    o-Phosphohomoserine

    		 Endogenous Metabolite iGluR Others
    O-Phosphono-L-homoserine (o-Phosphohomoserine) is an intermediate in threonine synthesis in bacteria and plants, and can also be hijacked by MetM in some Streptomyces species to enter a novel methionine synthesis pathway. O-Phosphono-L-homoserine acts as a weak antagonist of the NMDA receptor. O-Phosphono-L-homoserine can be used as a substrate for studies on amino acid metabolism of the aspartate family, a control for mechanism studies of PLP enzymes, and a reference for structure-activity relationship studies of NMDA receptor ligands .
    O-Phosphono-L-homoserine
  • HY-182548
    BTS 72664

    		GABA Receptor Sodium Channel iGluR Cardiovascular Disease Neurological Disease
    BTS 72664 is a broad-spectrum, non-sedating, orally effective anticonvulsant. Its anticonvulsant effect mainly arises from enhancing GABAA receptor (GABAA receptor)-mediated chloride channel currents, while it exerts weak blocking effects on Na + channels (Ki = 350 μM) and NMDA receptors (NMDA receptor) (IC50 = 43 μM). BTS 72664 prevents the elevation of extracellular glutamate, glycine and serine concentrations in neurons, reduces cerebral infarct size, promotes functional recovery, prevents multiple types of epileptic seizures, and has low sedative potential. BTS 72664 can be used for the research of epilepsy, stroke and migraine .
    BTS 72664
  • HY-15080
    GYKI 53405

    LY 293606

    		 iGluR Cardiovascular Disease Neurological Disease
    GYKI 53405 is a non-competitive, orally active AMPA receptor antagonist. GYKI 53405 shows no significant binding affinity for GABAA, GABAB or benzodiazepine receptors. GYKI 53405 increases self-grooming behavior, induces wet dog-like shakes, reduces spontaneous activity, produces anxiolytic-like behavior, reverses the anxiogenic effect induced by mCPP, inhibits locomotor activity, suppresses sound-induced and maximal electroshock-induced seizures, prolongs survival in global cerebral ischemia models, and exhibits sustained anticonvulsant effects at doses below the sedation threshold. GYKI 53405 can be used in research related to absence epilepsy, anxiety disorders and global cerebral ischemia .
    GYKI 53405

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: